
-
Mesoblast NASDAQ:MESO
Location: L 38 55 Collins St, Victoria, 3000, Australia | Website: http://www.mesoblast.com/ | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
18.74B
Cash
62.96M
Avg Qtr Burn
-12.11M
Short % of Float
0.35%
Insider Ownership
0.07%
Institutional Own.
2.49%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RYONCIL™ (Remestemcel-L) Details Acute graft-versus host disease | Approved Quarterly sales | |
REVASCOR® (Rexlemestrocel) Details Heart disease, Hypoplastic Left Heart Syndrome | BLA Acceptance for review | |
REVASCOR® (Rexlemestrocel) Details Heart disease, Heart failure | BLA FDA meeting | |
Rexlemestrocel Details Chronic lower back pain | Phase 3 Update | |
Remestemcel-L Details Inflammatory bowel disease, Bowel disorder, Crohns disease | Failed Discontinued | |
Failed Discontinued |